Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2020 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, 2019
Slide 1: Q1 FY2020 Earnings Presentation
Providing Affordable and Innovative medicines for healthier lives Q1 FY2020 Earnings Presentation 1 www.lincolnpharma.com
Slide 2: Highlights
Highlights Q1 FY2020 vs. Q4 FY2019 Management Perspective “We are pleased to report robust financial performance during the quarter. The o Total Income of Rs. 981 million, up 25.1% Company has recorded a 97% q-o-q EBITDA growth and 50% q-o-q PAT growth during Q1 FY2020. The growth has been attribute
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q1 y-o-y Q4 q-o-q Particulars FY2020 FY2019 Growth (%) FY2019 Growth (%) Total Income 981.1 1,021.2 (3.9)% 784.5 25.1% EBITDA 203.4 255.9 (20.5)% 103.1 97.2% Margin (%) 20.7% 25.1% 13.1% PBT 178.5 226.8 (21.3)% 78.8 126.6% Margin (%) 18.2% 22.2
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 20.2% 24.8% 25.0% Respiratory Systems Therapeutic Area 29.7% 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones 7.0% 13% 0.2% 15% Musculo-Skeletal System Q1 FY20 3.1% 14% Q1 FY19 Parasitology 0.1%
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) 15.4% 15.5% 2.2% (3.9)% (33.0)% 1,021.2 1,070.4 848.1 784.5 981.1 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 EBITDA (Rs. million) and Margin (%) 25.1% 22.0% 20.7% 16.5% 13.1% 255.9 235.2 139.9 103.1 203.4 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19
Slide 6: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 0.29x 0.97x 0.22x 0.18x 0.18x 0.56x 0.54x 0.15x 0.47x 0.37x Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 ROCE1 RONW2 24.3% 22.8% 21.6% 19.0% 19.6% 19.2% 18.8% 17.9% 18.1% 16.0% Q1 FY19 Q2 FY19 Q3 FY19 Q
Slide 7: Leverage Profile
Leverage Profile (Rs. million) June 2019 Mar 2019 Credit Rating Long Term Debt 48 54 o CRISIL Short Term Debt 377 734 Long term bank facilities: A-/Stable Total Debt 425 787 Short term bank facilities: A2+ o ICRA Less: Cash & Cash Equivalents 176 76 Long term bank facilities: A- Net Debt / (Ne
Slide 8: Recent Developments
Recent Developments 1 Becomes the producer of renewable power energy for captive consumption • In addition to two windmills, the Company has also set up a new Solar Plant of 1 MW at factory’s rooftop with a capacity of producing 15 Lakh Power Unit PA 2 Setting up API production unit • Applied to Pol
Slide 9: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 4.0% 3.2% 2.4% 2.0% 2.7% 148.1 Senior Scientist 15 117.3 Junior Scientist 18 1.6% 88.5 Analysts 18 79.5 72.6 Regulatory Personnel 12 Administrative Personnel 9 34.3 Others 6 Total 78 FY14 FY15 FY16 FY17 FY18 FY19 Q
Slide 10: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 4 Patents granted 1,700 Registered products 60+ 25 25 Patents applications 700 in pipeline Countries States across India 300+ 72nd 15+ Formulations developed Rank in AIOCD Therapeutic areas 650
Slide 11: Key Milestones
Key Milestones Received WHO – Becomes Public Covered 80% Installed Windmill Developed & Launch 3 products which are Targeting Many New GMP for plant / Limited Company of all India 600 KVA launched 2 more first time in India. Entered in Countries in West Africa & production unit from a Partnership Ma
Slide 12: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 25 States across India Jammu Uttaranchal Chandigarh Delhi Europe: Ambala Ghaziabad France Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada C
Slide 13: Best in Class Facilities
Best in Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Cap
Slide 14: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-diuretics/ Anti-malarial Anti-viral/ Anti-
Slide 15: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 α-β Arteether Injection Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride 150mg/ 2 ml Effective Anti- Malarial Kingping Heparin
Slide 16: Key Developments
Key Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better patient com
Slide 17: Key Developments
Key Developments o Domi Up Spray • Meter dose pump • Each squirt (spray) accurately delivers 2 mg Ondansetron Hydrochloride • Faster onset of action • Prompt relief from nausea & vomiting • Convenient for patient over Injectable • Better patients compliance o Namcold DX • First time in India: ‘Exten
Slide 18: Key Developments
Key Developments o USP INFITY - HS • Revitalized the DPC • Covering all aspects of Baldness in one solution • Powered with the Hair Growth Formula • Empowered with Powerful Antioxidant than Vitamin E or Vitamin C Q1 FY2020 Earnings Presentation 18
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060. Gujarat, INDIA. Phone :+91-79-4107 8000 • Fax:+91-79-4107 8062 E-mail: info@lincolnpharma.com www.lincolnpharma.com CIN: L24230GJ1995PLC024288 KP Sompura Finance Head, Lincoln Pharmaceuticals sompurakp@
Lincoln Pharmaceuticals — Q1 FY2020 Earnings Presentation on 6ix